Grant: Project Grant
University of Ottawa
$715,275.00
Targeted Covalent Inhibitors of Tissue Transglutaminase as Novel Anti-Cancer Therapeutics
FY 2018-19
Summary
Tissue transglutaminase (TG2) is a multifunctional enzyme that catalyses the cross-linking of proteins outside the cell, and participates in signalling inside the cell. However, a growing body of recent evidence has linked the unregulated activity of this enzyme to the spreading of cancer cells and the development of drug resistance. In light of this, we have developed inhibitors against TG2 that halt the proliferation of cancer cells and render them more susceptible to chemotherapy. We will optimize these inhibitors for in vivo application and validate the role of TG2 in cancer, in order to develop new and better methods for the treatment of cancer.
Department
Program
Project Grant
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
389836
Name
Keillor Jeffrey W
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Pharmaceutical Sciences
Projecttitle
Targeted Covalent Inhibitors of Tissue Transglutaminase as Novel Anti-Cancer Therapeutics
Programtype2
Operating Grants
Orgnameinp2
University of Ottawa
Cihramount2
$715,275
Cihrequipment2
$0
Programname2
Project Grant
Keyworddelim
Cancer; Cancer Stem Cells; Chemoresistance; Drug Design; G-Protein; Medicinal Chemistry; Metastasis; Pharmacodynamics; Pharmacokinetics; Transglutaminase
Abstract
Tissue transglutaminase (TG2) is a multifunctional enzyme that catalyses the cross-linking of proteins outside the cell, and participates in signalling inside the cell. However, a growing body of recent evidence has linked the unregulated activity of this enzyme to the spreading of cancer cells and the development of drug resistance. In light of this, we have developed inhibitors against TG2 that halt the proliferation of cancer cells and render them more susceptible to chemotherapy. We will optimize these inhibitors for in vivo application and validate the role of TG2 in cancer, in order to develop new and better methods for the treatment of cancer.
Competitiondate
201809
Approvedterm2
5 yrs 0 mth
Pinamesdelim
Keillor, Jeffrey W
Approvedterm
5 ans 0 mois
Cihrcontribution2
~ $715,275~ $0~
